Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer

por Hohaus, S, Funk, L, Martin, S, Schlenk, R F, Abdallah, A, Hahn, U, Egerer, G, Goldschmidt, H, Schneeweiß, A, Fersis, N, Kaul, S, Wallwiener, D, Bastert, G, Haas, R
Publicado 1999

PB2270: CLEARANCE OF PERSISTENT SARS-COV2 INFECTION WITH ANTIBODY CONTAINING PLASMA IN LEUKEMIA AND LYMPHOMA PATIENTS

por Janssen, M., Leo, A., Wolf, C., Bartenschlager, R., Schmitt, A., Haberbosch, I., Brandt, J., Sauer, S., Zeier, M., Meuer, S., Schmitt, M., Dreger, P., Schlenk, R. F., Müller-Tidow, C., Denkinger, C. M.
Publicado 2022

Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT

por Bohl, S, von Harsdorf, S, Mulaw, M, Hofmann, S, Babiak, A, Maier, C P, Schnell, J, Hütter-Krönke, L-M, Scholl, K, Wais, V, Schlenk, R F, Bullinger, L, Ringhoffer, M, Döhner, H, Bunjes, D, Bommer, M, Kuchenbauer, F
Publicado 2016

Randomized phase-III study of low-dose cytarabine and etoposide + /− all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia

por Schlenk, R. F., Weber, D., Krzykalla, J., Kindler, T., Wulf, G., Hertenstein, B., Salih, H. R., Südhoff, T., Krauter, J., Martens, U., Wessendorf, S., Runde, V., Tischler, H. J., Bentz, M., Koller, E., Heuser, M., Thol, F., Benner, A., Ganser, A., Döhner, K., Döhner, H.
Publicado 2023

Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial

por Heilig, C.E., Horak, P., Kreutzfeldt, S., Teleanu, V., Mock, A., Renner, M., Bhatti, I.A., Hutter, B., Hüllein, J., Fröhlich, M., Uhrig, S., Süße, H., Heiligenthal, L., Ochsenreither, S., Illert, A.L., Vogel, A., Desuki, A., Heinemann, V., Heidegger, S., Bitzer, M., Scheytt, M., Brors, B., Hübschmann, D., Baretton, G., Stenzinger, A., Steindorf, K., Benner, A., Jäger, D., Heining, C., Glimm, H., Fröhling, S., Schlenk, R.F.
Publicado 2021

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

por Schlenk, R F, Frech, P, Weber, D, Brossart, P, Horst, H-A, Kraemer, D, Held, G, Ringhoffer, M, Burchardt, A, Kobbe, G, Götze, K, Nachbaur, D, Fischer, T, Lübbert, M, Salih, H R, Salwender, H, Wulf, G, Koller, E, Wattad, M, Fiedler, W, Kremers, S, Kirchen, H, Hertenstein, B, Paschka, P, Gaidzik, V I, Teleanu, V, Heuser, M, Thol, F, Döhner, K, Krauter, J, Ganser, A, Döhner, H
Publicado 2017

Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia

por Jaramillo, S, Benner, A, Krauter, J, Martin, H, Kindler, T, Bentz, M, Salih, H R, Held, G, Köhne, C-H, Götze, K, Lübbert, M, Kündgen, A, Brossart, P, Wattad, M, Salwender, H, Hertenstein, B, Nachbaur, D, Wulf, G, Horst, H-A, Kirchen, H, Fiedler, W, Raghavachar, A, Russ, G, Kremers, S, Koller, E, Runde, V, Heil, G, Weber, D, Göhring, G, Döhner, K, Ganser, A, Döhner, H, Schlenk, R F
Publicado 2017

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine

por Schlenk, R. F., Weber, D., Herr, W., Wulf, G., Salih, H. R., Derigs, H. G., Kuendgen, A., Ringhoffer, M., Hertenstein, B., Martens, U. M., Grießhammer, M., Bernhard, H., Krauter, J., Girschikofsky, M., Wolf, D., Lange, E., Westermann, J., Koller, E., Kremers, S., Wattad, M., Heuser, M., Thol, F., Göhring, G., Haase, D., Teleanu, V., Gaidzik, V., Benner, A., Döhner, K., Ganser, A., Paschka, P., Döhner, H.
Publicado 2019

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)

por Nagel, Gabriele, Weber, D., Fromm, E., Erhardt, S., Lübbert, M., Fiedler, W., Kindler, T., Krauter, J., Brossart, P., Kündgen, A., Salih, H. R., Westermann, J., Wulf, G., Hertenstein, B., Wattad, M., Götze, K., Kraemer, D., Heinicke, T., Girschikofsky, M., Derigs, H.G., Horst, H. A., Rudolph, C., Heuser, M., Göhring, G., Teleanu, V., Bullinger, L., Thol, F., Gaidzik, V. I., Paschka, P., Döhner, K., Ganser, A., Döhner, Hartmut, Schlenk, R. F.
Publicado 2017

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS

por Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R. S., Sekeres, M. A., Della Porta, M. G., Cazzola, M., DeZern, A. E., Roboz, G. J., Steensma, D. P., Van de Loosdrecht, A. A., Schlenk, R. F., Grau, J., Calvo, X., Blum, S., Pereira, A., Valent, P., Costa, D., Giagounidis, A., Xicoy, B., Döhner, H., Platzbecker, U., Pedro, C., Lübbert, M., Oiartzabal, I., Díez-Campelo, M., Cedena, M. T., Machherndl-Spandl, S., López-Pavía, M., Baldus, C. D., Martinez-de-Sola, M., Stauder, R., Merchan, B., List, A., Ganster, C., Schroeder, T., Voso, M. T., Pfeilstöcker, M., Sill, H., Hildebrandt, B., Esteve, J., Nomdedeu, B., Cobo, F., Haas, R., Sole, F., Germing, U., Greenberg, P. L., Haase, D., Sanz, G.
Publicado 2020